Vitamin price drops but BASF nutrition sees 4% sales growth

By Shane Starling

- Last updated on GMT

Related tags: Revenue

Vitamin price drops but BASF nutrition sees 4% sales growth
BASF’s nutrition and health unit (N&H) earned €492m in Q3 – 4% more for the quarter than in 2011 when it had sales of €471m – despite falling prices for most vitamins.

The unit contributed just over 10% of the €4.015bn quarterly revenue for the Performance Products division that includes care, paper and performance chemicals.

For the first three quarters of year the N&H unit grew sales 4% on 2011 to €1.477bn with Performance Products overall 9-month revenues at €12.136bn. For the same period the whole BASF group had sales of €59.081bn – up 6.6% on 2011.

But profits after extraordinary items were removed dropped 21% for the Performance Products division, from €403m to €325m for the quarter, and 10% from €1.266bn to €1.136bn for the three quarters to September.

We increased sales in the Nutrition & Health division, mainly owing to positive currency effects and demand-driven higher sales volumes in almost all business areas,”​ BASF said.

Lower sales prices for vitamins, however, had a negative impact on sales and earnings. Increased raw material costs could only be partly passed on to the market, putting pressure on margins. Earnings were therefore significantly below the good level of the previous third quarter.”

But the company did not reveal the specific earnings for the N&H unit.

More broadly, chief executive Kurt Bock singled out the economic downturn and slower Chinese activity as major impacts on the German giant’s business.

“In the past quarter, the outlook for the world economy has once again not improved and the uncertainty on the international capital markets continues,”​ Bock said.

“In China, growth in the third quarter of 2012 has slowed once again compared with the same quarter of the previous year. We see stabilisation at the current level in China, but no visible upturn.”

The company was not available for further comment at the time of publication.

BASF bolstered its N&H division significantly at the end of 2010 when it bought Cognis for about €3bn.

Related news

Show more

Related products

show more

Business case: private label iron supplements

Business case: private label iron supplements

PharmaLinea Ltd. | 18-May-2021 | Case Study

A line of clinically supported private label iron supplements by PharmaLinea is selling nearly 500.000 units/year in a market of under 20 million people.

Divi’s extensive Vitamin D2 and D3 portfolio

Divi’s extensive Vitamin D2 and D3 portfolio

Divis Nutraceuticals | 18-May-2021 | Product Brochure

As an expert in the formulation of fat-soluble vitamins, Divi's offers a large portfolio of vitamins D2 and D3 in the form of spray-dried powders,...

Innovation: L-Vital C®, true liposomal vitamin C

Innovation: L-Vital C®, true liposomal vitamin C

CAPSULARIS | 14-Apr-2021 | Product Brochure

Did you know that the liquid liposomal vitamin is the form of vitamin C that is best utilized by the body? Liposomes need aqueous solutions to live and...

HydroCurc + Fe = Smart Formula

HydroCurc + Fe = Smart Formula

Gencor | 02-Mar-2021 | Clinical Study

Iron deficiency is the most prevalent micronutrient deficiency in the world and can have impacts on physical and mental health. A critical micronutrient...

Related suppliers

Follow us

Products

View more

Webinars